Enrolling Studies

See a list of our enrolling studies and research information. Access current studies and clinical trial data.

Treatment Naïve and Previously Treated Wet AMD

Sponsor: Ocular Therapeutix OTX-LR

Study Drug: Sustained-release Tyrosine Kinase Inhibitor (Intravitreal Injection)

Control Arm: Aflibercept 50y/o

Inclusion/Exclusion Criteria: BCVA-20/80 or better in study eye, 20/200 or better in fellow eye CST-<500um

Other: Sponsor covers fellow eye treatment (any drug)

Previously-treated Wet AMD

Sponsor: Regenxbio

Study Drug: Subretinal Gene Therapy (coding for Ranibizumab) (Surgical)

Control Arm: Ranibizumab or Aflibercept

Inclusion/Exclusion Criteria: BCVA- 20/40-20/100 <10 injections in last year 4 years since Wet AMD diagnosis; 50490 γ/ο PED <400um; no macular atrophy PCIOL

Treatment Naïve/Previously Treated Wet AMD

Sponsor: Eyepoint Lugano Study

Study Drug: Sustained-release Tyrosine Kinase Inhibitor (Intravitreal Injection)

Control Arm: Afilbercept

Inclusion/Exclusion Criteria: 50v/o BCVA-20/32-20/200 >2 injections in last 6 months CST <500um

No Atrophy or scarring centrally

Treatment naive/Previously treated Diabetic Macular Edema

Sponsor: Oculis Diamond Study

Study Drug: Topical dexamethasone drops

Control Arm: Sham 18-85y/o

Inclusion/Exclusion Criteria: BCVA 20/50-20/320 in study eye; 20/40-20/200 fellow eye CST-310um

Washout: >3 month anti-VEGF; 6 month Ozurdex No steroids (topical, oral, IM, IV, nasal) in last month

No contact lens users

RegenxBio – RGX-314-2202

A Phase 2, Randomized, Dose-escalation, Observation-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of RGX-314 Gene Therapy Delivered via One or Two Suprachoroidal Space (SCS) Injections in Participants with Diabetic Retinopathy (DR) Without Center Involved-Diabetic Macular Edema (CI-DME) (ALTITUDE).

Diabetic Retinopathy w/ & w/o DME

Sponsor: Regenexbio

Study Drug: Suprachoroidal Gene Therapy (coding for Ranibizumab) (Suprachoroidal Injection)

Control Arm: Aflibercept

Inclusion/Exclusion Criteria: 25-89y/o
BCVA- 20/32-20/320 in study eye;
Mod NPDR-Early PDR
CST>325um (in DME arm)
Washout: >6month anti-VEGF/steroid <10 injections in last 3 years H/o PRP or surgery DME > 7 years

Upcoming Studies

Regeneron GA – Subcutaneous monthly injection of anti-complement agent

Astellas GA- Phase 4 observational study of patients receiving Izervay treatment

Genentech DME Tiež activator in combo with Aflibercept/Farcimab

Advarum Wet AMD Intravitreal injection of genetherapy coding for Aflibercept